View Future GrowthOrganoClick 과거 순이익 실적과거 기준 점검 0/6OrganoClick은 연평균 5.8%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 연평균 9.5%의 비율로 증가했습니다. 매출은 연평균 1.4%의 비율로 증가했습니다.핵심 정보5.79%순이익 성장률7.28%주당순이익(EPS) 성장률Chemicals 산업 성장률32.95%매출 성장률1.35%자기자본이익률-192.32%순이익률-35.17%다음 순이익 업데이트12 Aug 2026최근 과거 실적 업데이트Reported Earnings • May 12First quarter 2026 earnings: EPS in line with expectations, revenues disappointFirst quarter 2026 results: kr0.015 loss per share (improved from kr0.036 loss in 1Q 2025). Revenue: kr27.4m (down 23% from 1Q 2025). Net loss: kr1.66m (loss narrowed 53% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 15Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: kr0.36 loss per share (further deteriorated from kr0.18 loss in FY 2024). Revenue: kr106.2m (down 17% from FY 2024). Net loss: kr36.4m (loss widened 102% from FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 1.1% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.공고 • Dec 10+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2025 Final Results on Apr 08, 2026OrganoClick AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 08, 2026Reported Earnings • Nov 06Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: kr0.08 loss per share (further deteriorated from kr0.047 loss in 3Q 2024). Revenue: kr22.5m (down 22% from 3Q 2024). Net loss: kr8.08m (loss widened 75% from 3Q 2024). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.4% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 20Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: kr0.065 loss per share (further deteriorated from kr0.029 loss in 2Q 2024). Revenue: kr30.0m (down 23% from 2Q 2024). Net loss: kr6.37m (loss widened 124% from 2Q 2024). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 200%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 09Full year 2024 earnings: EPS in line with expectations, revenues disappointFull year 2024 results: kr0.18 loss per share (further deteriorated from kr0.16 loss in FY 2023). Revenue: kr127.2m (down 13% from FY 2023). Net loss: kr18.0m (loss widened 14% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공고 • Jul 11OrganoClick AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 32.947243 million.OrganoClick AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 32.947243 million. Security Name: Shares Security Type: Common Stock Securities Offered: 73,216,096 Price\Range: SEK 0.45 Transaction Features: Rights OfferingBoard Change • Jun 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Johan Magnusson was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Jun 04OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 39.601085 million.OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 39.601085 million. Security Name: Shares Security Type: Common Stock Securities Offered: 88,002,412 Price\Range: SEK 0.45 Transaction Features: Rights OfferingReported Earnings • May 12First quarter 2026 earnings: EPS in line with expectations, revenues disappointFirst quarter 2026 results: kr0.015 loss per share (improved from kr0.036 loss in 1Q 2025). Revenue: kr27.4m (down 23% from 1Q 2025). Net loss: kr1.66m (loss narrowed 53% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.공고 • Apr 24OrganoClick AB (publ), Annual General Meeting, May 26, 2026OrganoClick AB (publ), Annual General Meeting, May 26, 2026, at 16:00 W. Europe Standard Time. Location: organoclick`s head office at linjalvagen 9 in taby, Sweden분석 기사 • Feb 15OrganoClick AB (publ) (STO:ORGC) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportOrganoClick AB (publ) ( STO:ORGC ) missed earnings with its latest yearly results, disappointing overly-optimistic...Reported Earnings • Feb 15Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: kr0.36 loss per share (further deteriorated from kr0.18 loss in FY 2024). Revenue: kr106.2m (down 17% from FY 2024). Net loss: kr36.4m (loss widened 102% from FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 1.1% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Major Estimate Revision • Jan 23Consensus EPS estimates fall by 21%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -kr0.24 to -kr0.29 per share. Revenue forecast unchanged at kr110.0m. Chemicals industry in Sweden expected to see average net income growth of 27% next year. Consensus price target of kr2.00 unchanged from last update. Share price fell 5.4% to kr1.66 over the past week.Breakeven Date Change • Jan 22Forecast breakeven date pushed back to 2028The analyst covering OrganoClick previously expected the company to break even in 2027. New forecast suggests the company will make a profit of kr4.00m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule.공고 • Dec 10+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2025 Final Results on Apr 08, 2026OrganoClick AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 08, 2026분석 기사 • Nov 08Analysts Have Been Trimming Their OrganoClick AB (publ) (STO:ORGC) Price Target After Its Latest ReportOrganoClick AB (publ) ( STO:ORGC ) missed earnings with its latest quarterly results, disappointing overly-optimistic...Reported Earnings • Nov 06Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: kr0.08 loss per share (further deteriorated from kr0.047 loss in 3Q 2024). Revenue: kr22.5m (down 22% from 3Q 2024). Net loss: kr8.08m (loss widened 75% from 3Q 2024). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.4% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.New Risk • Nov 05New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr23m Forecast net loss in 2 years: kr4.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr4.0m net loss in 2 years). Share price has been volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$100m (kr195.8m market cap, or US$20.4m).Recent Insider Transactions • Aug 17Independent Director recently bought kr105k worth of stockOn the 14th of August, Chatarina Schneider bought around 60k shares on-market at roughly kr1.76 per share. This transaction amounted to 81% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.3m more in shares than they have sold in the last 12 months.Board Change • Aug 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Johan Magnusson was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Jul 23OrganoClick AB (publ) (STO:ORGC) Analysts Are Cutting Their Estimates: Here's What You Need To KnowAs you might know, OrganoClick AB (publ) ( STO:ORGC ) last week released its latest quarterly, and things did not turn...Reported Earnings • Jul 20Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: kr0.065 loss per share (further deteriorated from kr0.029 loss in 2Q 2024). Revenue: kr30.0m (down 23% from 2Q 2024). Net loss: kr6.37m (loss widened 124% from 2Q 2024). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 200%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Breakeven Date Change • Jul 18The analyst covering OrganoClick previously expected the company to break even in 2027. New forecast suggests losses will reduce by 53% per year to 2026. The company is expected to make a profit of kr3.20m in 2027. Average annual earnings growth of 78% is required to achieve expected profit on schedule.공고 • Jul 18OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.31619 million.OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.31619 million. Security Name: Shares Security Type: Common Stock Securities Offered: 11,543,290 Price\Range: SEK 1.76 Transaction Features: Rights Offering분석 기사 • Jul 16OrganoClick (STO:ORGC) Is Making Moderate Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Major Estimate Revision • Jul 10Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr135.0m to kr130.0m. Losses expected to increase from kr0.14 per share to kr0.16. Chemicals industry in Sweden expected to see average net income growth of 37% next year. Consensus price target of kr2.50 unchanged from last update. Share price rose 7.5% to kr2.15 over the past week.공고 • May 20OrganoClick AB (publ) Approves Board ChangesOrganoClick AB (publ) announced at the AGM held on May 20, 2025, approved Johan Magnusson was elected as Chairman of the Board. The Board also gave a big thank to the outgoing Chairman of the board Jan Johansson for his contribution to the board and the company during his 9 years as Chairman of the board.Recent Insider Transactions • May 15Independent Director recently bought kr129k worth of stockOn the 8th of May, Johan Magnusson bought around 60k shares on-market at roughly kr2.15 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger purchase from another insider worth kr1.0m. Insiders have collectively bought kr1.2m more in shares than they have sold in the last 12 months.분석 기사 • May 14It's Probably Less Likely That OrganoClick AB (publ)'s (STO:ORGC) CEO Will See A Huge Pay Rise This YearKey Insights OrganoClick to hold its Annual General Meeting on 20th of May Total pay for CEO Marten Hellberg includes...Major Estimate Revision • May 13Consensus EPS estimates fall by 40%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr140.0m to kr135.0m. Losses expected to increase from kr0.10 per share to kr0.14. Chemicals industry in Sweden expected to see average net income growth of 41% next year. Consensus price target of kr2.50 unchanged from last update. Share price fell 11% to kr2.05 over the past week.분석 기사 • May 09kr2.50: That's What Analysts Think OrganoClick AB (publ) (STO:ORGC) Is Worth After Its Latest ResultsThe analyst might have been a bit too bullish on OrganoClick AB (publ) ( STO:ORGC ), given that the company fell short...New Risk • May 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr5.5m free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$100m (kr260.0m market cap, or US$26.9m).분석 기사 • May 05Cautious Investors Not Rewarding OrganoClick AB (publ)'s (STO:ORGC) Performance CompletelyOrganoClick AB (publ)'s ( STO:ORGC ) price-to-sales (or "P/S") ratio of 1.9x might make it look like a buy right now...New Risk • May 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr5.5m free cash flow). Minor Risk Market cap is less than US$100m (kr245.3m market cap, or US$25.4m).Major Estimate Revision • Apr 30Consensus EPS estimates fall by 67%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr143.0m to kr140.0m. Losses expected to increase from kr0.06 per share to kr0.10. Chemicals industry in Sweden expected to see average net income growth of 38% next year. Consensus price target of kr2.50 unchanged from last update. Share price fell 3.3% to kr2.34 over the past week.공고 • Apr 16OrganoClick AB (publ), Annual General Meeting, May 20, 2025OrganoClick AB (publ), Annual General Meeting, May 20, 2025, at 13:00 W. Europe Standard Time. Location: at convendum, brahegatan 10, stockholm SwedenReported Earnings • Apr 09Full year 2024 earnings: EPS in line with expectations, revenues disappointFull year 2024 results: kr0.18 loss per share (further deteriorated from kr0.16 loss in FY 2023). Revenue: kr127.2m (down 13% from FY 2023). Net loss: kr18.0m (loss widened 14% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Feb 27Director recently bought kr1.0m worth of stockOn the 25th of February, Charlotte Jansdotter Karlberg bought around 400k shares on-market at roughly kr2.50 per share. This transaction increased Charlotte Jansdotter's direct individual holding by 5x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.0m more in shares than they have sold in the last 12 months.Reported Earnings • Feb 15Full year 2024 earnings: EPS in line with expectations, revenues disappointFull year 2024 results: kr0.18 loss per share (further deteriorated from kr0.16 loss in FY 2023). Revenue: kr127.2m (down 13% from FY 2023). Net loss: kr18.0m (loss widened 14% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.분석 기사 • Feb 14Would OrganoClick (STO:ORGC) Be Better Off With Less Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...New Risk • Feb 13New major risk - Revenue and earnings growthEarnings have declined by 1.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.4% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr4.5m). Market cap is less than US$100m (kr263.0m market cap, or US$24.2m).공고 • Feb 13OrganoClick AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025OrganoClick AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 03, 2025공고 • Dec 03+ 3 more updatesOrganoClick AB (publ) to Report Q1, 2025 Results on May 06, 2025OrganoClick AB (publ) announced that they will report Q1, 2025 results on May 06, 2025Reported Earnings • Nov 07Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: kr0.047 loss per share (further deteriorated from kr0.042 loss in 3Q 2023). Revenue: kr28.9m (down 14% from 3Q 2023). Net loss: kr4.62m (loss widened 12% from 3Q 2023). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 150%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.New Risk • Nov 06New major risk - Revenue and earnings growthEarnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr284.5m market cap, or US$26.2m).New Risk • Oct 29New major risk - Revenue and earnings growthEarnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr288.5m market cap, or US$27.0m).Breakeven Date Change • Jul 22Forecast to breakeven in 2025The analyst covering OrganoClick expects the company to break even for the first time. New forecast suggests the company will make a profit of kr6.00m in 2025. Average annual earnings growth of 109% is required to achieve expected profit on schedule.Reported Earnings • Jul 22Second quarter 2024 earnings released: kr0.029 loss per share (vs kr0.027 loss in 2Q 2023)Second quarter 2024 results: kr0.029 loss per share (further deteriorated from kr0.027 loss in 2Q 2023). Revenue: kr38.7m (down 5.6% from 2Q 2023). Net loss: kr2.85m (loss widened 6.6% from 2Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.Major Estimate Revision • Jul 07Consensus EPS estimates fall by 17%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr158.0m to kr155.0m. Losses expected to increase from kr0.06 per share to kr0.07. Chemicals industry in Sweden expected to see average net income growth of 33% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.78 over the past week.분석 기사 • Jun 19A Piece Of The Puzzle Missing From OrganoClick AB (publ)'s (STO:ORGC) 26% Share Price ClimbOrganoClick AB (publ) ( STO:ORGC ) shareholders have had their patience rewarded with a 26% share price jump in the...공고 • Jun 15OrganoClick AB (publ) Announces CFO ChangesOrganoClick AB (publ) has appointed Carin Eklund as the new CFO for the group. She will lead OrganoClick's finance and economics department and be part of the group's management team. Carin has more than 20 years of experience from various finance functions from, among others, Bristol Myers Squibb group, ByggFakta group and Team Olivia group. Carin has a M. Sc. in Economics with a specialization in financial mathematics at Karlstad University. For more than 25 years, Carin has worked in finance departments at both manufacturing companies and service companies, in both smaller companies and large groups. Previous experiences include roles as CFO for Olivia Hemomsorg, Finance manager for the medical technology company Convatec (part of the Bristol Myers Squibb Group), Head of Business Control Nordic region at ByggFakta Group and as Strategic Controller at the kitchen manufacturer Nobia. Carin takes over as CFO on July 15, and as previously announced, OrganoClick's current CFO Jessica Sundborg will leave the company 21 of August.공고 • May 16OrganoClick AB (publ) Approves Board ChangesOrganoClick AB (publ) at its Annual General Meeting held on 15 May 2024 approved the election of Johan Magnusson as board member. The Board also gave a big thank to the outgoing board member Malin Bugge for her contribution to the board and the company during her 4 years as a board member.분석 기사 • May 09Shareholders May Find It Hard To Justify Increasing OrganoClick AB (publ)'s (STO:ORGC) CEO Compensation For NowKey Insights OrganoClick's Annual General Meeting to take place on 15th of May CEO Marten Hellberg's total compensation...분석 기사 • May 03Earnings Release: Here's Why Analysts Cut Their OrganoClick AB (publ) (STO:ORGC) Price Target To kr3.00Investors in OrganoClick AB (publ) ( STO:ORGC ) had a good week, as its shares rose 2.2% to close at kr3.30 following...Reported Earnings • May 02First quarter 2024 earnings: EPS in line with expectations, revenues disappointFirst quarter 2024 results: kr0.022 loss per share (further deteriorated from kr0.01 loss in 1Q 2023). Revenue: kr38.2m (down 12% from 1Q 2023). Net loss: kr2.11m (loss widened 112% from 1Q 2023). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.Major Estimate Revision • May 01Consensus EPS estimates upgraded to kr0.06 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from kr166.0m to kr158.0m. 2024 losses expected to reduce from -kr0.09 to -kr0.06 per share. Chemicals industry in Sweden expected to see average net income growth of 48% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.24 over the past week.New Risk • Apr 30New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr298.7m market cap, or US$27.3m).공고 • Apr 23OrganoWood AB (publ) Announces Three-Year Results from the Field Study EN 12037 for Organowood NowaOrganowood Nowa is currently subjected to one of the toughest standard field tests available for wood above ground, EN 12037! The test runs for 5 years in Malaysia and Denmark and now publish the three-year results. The independent external institute Dansk Teknologisk Institut therefore carries out the EN 12037 field test with Organowood Nowa in both Denmark and Malaysia. The references, which consist of untreated pine wood and the wood impregnated with CCA (chromium, copper and arenic), which has been banned for 20 years, were also included in the test. The scale for assessing degradation ranges from grade 0-4, where 0 meas that the wood is unaffected and 4 means that the wood is completely degraded. The untreated reference in Malaysia was completely degraded after 3 years, by rot fungus but also in some cases by termites. Pine pressure-impregnated with CCA was, as expected, unaffected. But also OrganoWood Nowa was completely unaffected with grade 0 on the scale! The result shows a very good wood protection even in the warm and humid environment that a rainforest offers. The field study will continue and will continuously report results from both Denmark and Malaysia.공고 • Apr 19Jessica Sundborg to Leave as CFO of OrganoClick AB (publ)OrganoClick AB (publ) announced that its CFO since 2013, Jessica Sundborg is leaving her position to move on to a new position outside the company. Jessica will remain as CFO until she leaves her position after the summer. The work to recruit a successor has begun.New Risk • Apr 17New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr308.5m market cap, or US$28.2m).공고 • Apr 11Organoclick AB (Publ) Announces That Malin Bugge, Board Member, Has Declined Re-ElectionOrganoClick AB (publ) announced that Malin Bugge, who has been a board member since 2020, has declined re-election.Reported Earnings • Apr 09Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: kr0.16 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr145.9m (up 27% from FY 2022). Net loss: kr15.8m (loss narrowed 65% from FY 2022). Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.분석 기사 • Mar 25Sentiment Still Eluding OrganoClick AB (publ) (STO:ORGC)With a price-to-sales (or "P/S") ratio of 2.4x OrganoClick AB (publ) ( STO:ORGC ) may be sending bullish signals at the...공고 • Mar 23OrganoClick and PulPac Launches Plastic-Free Coffee Lid Reducing Co2 Footprint with 80%OrganoClick and PulPac has collaborated for several years in developing 100% biobased and biodegradable dry-molded products. By combining PulPac's dry molded fiber technology with OrganoClick's biobased and biodegradable binders, a biobased high-performing coffee lid, compliant with paper recycling have been developed. The innovative coffee lid is now launched for the take away market. PulPac's technology in combination with OrganoClick's biobased binders sets a new standard for high performing and sustainable packaging. It requires less energy and water than the traditional method, resulting in a reduced carbon footprint with up to 80% compared to traditional alternatives. One of the first products out is a plastic-free coffee lid which align with the recent EU legislation for take away product. Annual global consumption of coffee lids is estimated at 100,000,000,000 and with the new coffee lid, the CO2 footprint is reduced with up to 80%. The coffee lid is made green inside with the support of OrganoClick's biobased, biodegradable and home compostable binder, in part manufactured from waste streams from the food industry. The use of OrganoClick's binder resulting in a paper lid with much higher performance. The objectives are also to replace as much as possible of traditional plastic lids available on the market, thereby reducing the risk for microplastics ending up in the environment.Major Estimate Revision • Feb 22Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr183.0m to kr170.0m. Losses expected to increase from kr0.08 per share to kr0.09. Chemicals industry in Sweden expected to see average net income growth of 42% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.16 over the past week.분석 기사 • Feb 18Earnings Update: OrganoClick AB (publ) (STO:ORGC) Just Reported And Analysts Are Trimming Their ForecastsLast week, you might have seen that OrganoClick AB (publ) ( STO:ORGC ) released its full-year result to the market. The...Reported Earnings • Feb 16Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: kr0.16 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr145.9m (up 27% from FY 2022). Net loss: kr15.8m (loss narrowed 65% from FY 2022). Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.New Risk • Jan 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr13m). Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (kr297.8m market cap, or US$28.5m).Major Estimate Revision • Jan 19Consensus EPS estimates upgraded to kr0.14 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -kr0.17 to -kr0.14 per share. Revenue forecast steady at kr148.0m. Chemicals industry in Sweden expected to see average net income growth of 1.1% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.18 over the past week.분석 기사 • Jan 09OrganoClick (STO:ORGC) Seems To Use Debt Quite SensiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...공고 • Dec 20OrganoClick AB (publ), Annual General Meeting, May 15, 2024OrganoClick AB (publ), Annual General Meeting, May 15, 2024.공고 • Dec 19+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2024 Results on Feb 13, 2025OrganoClick AB (publ) announced that they will report fiscal year 2024 results on Feb 13, 2025Recent Insider Transactions • Nov 16Co-founder & CEO recently bought kr202k worth of stockOn the 13th of November, Marten Hellberg bought around 56k shares on-market at roughly kr3.63 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Marten has been a buyer over the last 12 months, purchasing a net total of kr211k worth in shares.New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr13m). Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (kr372.2m market cap, or US$34.3m).Reported Earnings • Nov 10Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: kr0.042 loss per share (improved from kr0.093 loss in 3Q 2022). Revenue: kr33.4m (up 50% from 3Q 2022). Net loss: kr4.13m (loss narrowed 55% from 3Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 33%. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.New Risk • Nov 09New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr14m). Market cap is less than US$100m (kr307.6m market cap, or US$28.3m).New Risk • Nov 03New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr14m). Market cap is less than US$100m (kr330.1m market cap, or US$30.3m).Breakeven Date Change • Nov 03Forecast to breakeven in 2025The analyst covering OrganoClick expects the company to break even for the first time. New forecast suggests the company will make a profit of kr7.90m in 2025. Average annual earnings growth of 107% is required to achieve expected profit on schedule.공고 • Oct 17OrganoClick AB (publ) Announces Nomination CommitteeOrganoClick AB (publ) announced composition of nomination committee. It is composed of Peter Lindell, representing Cidro Förvaltning and himself, Håkan Gustavson representing Beijer Ventures, the Beijer foundations, and himself, and Mårten Hellberg, representing M. Hellberg AB and himself. Peter Lindell was appointed as Chairman of the Nomination committee as the individually largest shareholder in OrganoClick AB.Recent Insider Transactions • Aug 24Chairman recently bought kr147k worth of stockOn the 18th of August, Jan Johansson bought around 35k shares on-market at roughly kr4.20 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jan has been a buyer over the last 12 months, purchasing a net total of kr352k worth in shares.Reported Earnings • Aug 18Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: kr0.03 loss per share (improved from kr0.09 loss in 2Q 2022). Revenue: kr41.0m (up 6.5% from 2Q 2022). Net loss: kr2.67m (loss narrowed 70% from 2Q 2022). Revenue missed analyst estimates by 5.2%. Earnings per share (EPS) exceeded analyst estimates by 25%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 13% per year.New Risk • Jul 19New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr40m Forecast net loss in 2 years: kr1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr31m). Currently unprofitable and not forecast to become profitable over next 2 years (kr1.4m net loss in 2 years). Market cap is less than US$100m (kr471.1m market cap, or US$45.8m).Major Estimate Revision • Jul 19Consensus EPS estimates fall by 25%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr166.5m to kr152.6m. Losses expected to increase from kr0.12 per share to kr0.15. Chemicals industry in Sweden expected to see average net income decline 1.4% next year. Consensus price target of kr9.00 unchanged from last update. Share price fell 4.7% to kr4.66 over the past week.공고 • Jun 01Organoclick Launches Biobased and Eco-Labelled Textile WaterproofingAfter several years of research and development, OrganoClick is launching, within its brand OrganoTex, a newly developed and eco-labelled textile waterproofing with world-unique performance on the trade fair ISPO Outdoor 4-6 June in Munich. Through green chemistry that mimics nature's own water repellency, an excellent environmental profile and high technical performance are achieved. The products are biobased, biodegradable and eco-labelled and completely free of PFAS, fossil plastics, and synthetic waxes. The technology is based on combining the natural fatty acids of plants and the surface structure of leaves with the Nobel Prize-winning chemistry organocatalysis. The inspiration is the lotus leaf with its 3D structure and extreme water repellency. To succeed in this, the patented OrganoClick technology is used to "click" the natural fatty acids on the textile fibers. The result is a new generation of OrganoTex products that have improved water repellency and withstand morewashing cycles. The products are biobase and biodegradable, and contain neither PFAS, fossil-based plastics nor synthetic waxes. First out are the products OrganoTex Wash-In Textile Waterproofing and OrganoTex Spray-On Textile Waterproofing. Thanks to their excellent environmental profile, they have received the environmental label Oeko-Tex Eco Passport and USDA BioPreferred Certified Biobased Product. The products are also verified to be readily biodegradable according to the high requirements of the OECD 301F test. A world-unique product that both combines high performance and at the same time is biobased, plastic-free and biodegradable and, of course, PFAS-free. This innovation is fully in line with OrganoClick's overall mission to accelerate the phasing out of plastics and fossil chemicals towards overall vision of a nature free of plastics and toxic chemicals.공고 • May 19Organoclick AB (Publ) Announces Board ChangesOrganoClick AB (publ) at its Annual General Meeting on 17 May 2023 the company approved and elect Chatarina Schneider as board members. And Board also gave a big thank to the outgoing board member Claes-Göran Beckeman for his important contribution to the board and the company during his 15 years as a board member.Major Estimate Revision • May 12Consensus estimates of losses per share improve by 25%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from kr162.1m to kr166.5m. EPS estimate increased from -kr0.16 per share to -kr0.12 per share. Chemicals industry in Sweden expected to see average net income growth of 0.2% next year. Consensus price target of kr9.00 unchanged from last update. Share price fell 17% to kr3.97 over the past week.분석 기사 • May 11Is OrganoClick AB (publ) (STO:ORGC) Potentially Undervalued?While OrganoClick AB (publ) ( STO:ORGC ) might not be the most widely known stock at the moment, it saw a decent share...분석 기사 • Apr 18There's No Escaping OrganoClick AB (publ)'s (STO:ORGC) Muted Revenues Despite A 33% Share Price RiseDespite an already strong run, OrganoClick AB (publ) ( STO:ORGC ) shares have been powering on, with a gain of 33% in...Reported Earnings • Apr 09Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: kr0.45 loss per share (further deteriorated from kr0.34 loss in FY 2021). Revenue: kr115.0m (up 4.5% from FY 2021). Net loss: kr44.4m (loss widened 36% from FY 2021). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Apr 06Chairman recently bought kr206k worth of stockOn the 3rd of April, Jan Johansson bought around 50k shares on-market at roughly kr4.11 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jan's only on-market trade for the last 12 months.Recent Insider Transactions • Feb 27Environmental & Sustainability Director recently bought kr120k worth of stockOn the 20th of February, Mattias Bodin bought around 30k shares on-market at roughly kr4.00 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.7m more in shares than they have sold in the last 12 months.매출 및 비용 세부 내역OrganoClick가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OM:ORGC 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비31 Mar 2698-3537731 Dec 25106-3640630 Sep 25109-2637630 Jun 25116-2336631 Mar 25124-1937631 Dec 24127-1837630 Sep 24134-1837730 Jun 24138-1737731 Mar 24141-1737731 Dec 23146-1637730 Sep 23140-2839730 Jun 23128-3341731 Mar 23126-4042831 Dec 22115-4443830 Sep 22111-3642830 Jun 22112-3542831 Mar 22113-3241731 Dec 21110-3340830 Sep 21110-3138730 Jun 21108-2938731 Mar 21104-2434631 Dec 2096-2433530 Sep 2093-2331530 Jun 2089-2330531 Mar 2086-2330531 Dec 1985-2029430 Sep 1984-1829430 Jun 1984-1829431 Mar 1982-1830431 Dec 1878-2031330 Sep 1878-2332330 Jun 1878-2432431 Mar 1875-2631431 Dec 1775-2831430 Sep 1769-2634330 Jun 1762-2636231 Mar 1751-2838131 Dec 1640-2939030 Sep 1638-2837030 Jun 1637-2535031 Mar 1633-2233031 Dec 1532-2031030 Sep 1530-17280양질의 수익: ORGC 은(는) 현재 수익성이 없습니다.이익 마진 증가: ORGC는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ORGC는 수익성이 없지만 지난 5년 동안 연평균 5.8%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ORGC의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ORGC은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(1.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ORGC는 현재 수익성이 없으므로 자본 수익률이 음수(-192.32%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/15 07:44종가2026/07/15 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스OrganoClick AB (publ)는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierJohan BrownABG Sundal Collier Sponsorednull nullABG Sundal Collier Sponsored1명의 분석가 더 보기
Reported Earnings • May 12First quarter 2026 earnings: EPS in line with expectations, revenues disappointFirst quarter 2026 results: kr0.015 loss per share (improved from kr0.036 loss in 1Q 2025). Revenue: kr27.4m (down 23% from 1Q 2025). Net loss: kr1.66m (loss narrowed 53% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 15Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: kr0.36 loss per share (further deteriorated from kr0.18 loss in FY 2024). Revenue: kr106.2m (down 17% from FY 2024). Net loss: kr36.4m (loss widened 102% from FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 1.1% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
공고 • Dec 10+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2025 Final Results on Apr 08, 2026OrganoClick AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 08, 2026
Reported Earnings • Nov 06Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: kr0.08 loss per share (further deteriorated from kr0.047 loss in 3Q 2024). Revenue: kr22.5m (down 22% from 3Q 2024). Net loss: kr8.08m (loss widened 75% from 3Q 2024). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.4% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 20Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: kr0.065 loss per share (further deteriorated from kr0.029 loss in 2Q 2024). Revenue: kr30.0m (down 23% from 2Q 2024). Net loss: kr6.37m (loss widened 124% from 2Q 2024). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 200%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 09Full year 2024 earnings: EPS in line with expectations, revenues disappointFull year 2024 results: kr0.18 loss per share (further deteriorated from kr0.16 loss in FY 2023). Revenue: kr127.2m (down 13% from FY 2023). Net loss: kr18.0m (loss widened 14% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
공고 • Jul 11OrganoClick AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 32.947243 million.OrganoClick AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 32.947243 million. Security Name: Shares Security Type: Common Stock Securities Offered: 73,216,096 Price\Range: SEK 0.45 Transaction Features: Rights Offering
Board Change • Jun 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Johan Magnusson was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Jun 04OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 39.601085 million.OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 39.601085 million. Security Name: Shares Security Type: Common Stock Securities Offered: 88,002,412 Price\Range: SEK 0.45 Transaction Features: Rights Offering
Reported Earnings • May 12First quarter 2026 earnings: EPS in line with expectations, revenues disappointFirst quarter 2026 results: kr0.015 loss per share (improved from kr0.036 loss in 1Q 2025). Revenue: kr27.4m (down 23% from 1Q 2025). Net loss: kr1.66m (loss narrowed 53% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
공고 • Apr 24OrganoClick AB (publ), Annual General Meeting, May 26, 2026OrganoClick AB (publ), Annual General Meeting, May 26, 2026, at 16:00 W. Europe Standard Time. Location: organoclick`s head office at linjalvagen 9 in taby, Sweden
분석 기사 • Feb 15OrganoClick AB (publ) (STO:ORGC) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportOrganoClick AB (publ) ( STO:ORGC ) missed earnings with its latest yearly results, disappointing overly-optimistic...
Reported Earnings • Feb 15Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: kr0.36 loss per share (further deteriorated from kr0.18 loss in FY 2024). Revenue: kr106.2m (down 17% from FY 2024). Net loss: kr36.4m (loss widened 102% from FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 1.1% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Jan 23Consensus EPS estimates fall by 21%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -kr0.24 to -kr0.29 per share. Revenue forecast unchanged at kr110.0m. Chemicals industry in Sweden expected to see average net income growth of 27% next year. Consensus price target of kr2.00 unchanged from last update. Share price fell 5.4% to kr1.66 over the past week.
Breakeven Date Change • Jan 22Forecast breakeven date pushed back to 2028The analyst covering OrganoClick previously expected the company to break even in 2027. New forecast suggests the company will make a profit of kr4.00m in 2028. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
공고 • Dec 10+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2025 Final Results on Apr 08, 2026OrganoClick AB (publ) announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 08, 2026
분석 기사 • Nov 08Analysts Have Been Trimming Their OrganoClick AB (publ) (STO:ORGC) Price Target After Its Latest ReportOrganoClick AB (publ) ( STO:ORGC ) missed earnings with its latest quarterly results, disappointing overly-optimistic...
Reported Earnings • Nov 06Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: kr0.08 loss per share (further deteriorated from kr0.047 loss in 3Q 2024). Revenue: kr22.5m (down 22% from 3Q 2024). Net loss: kr8.08m (loss widened 75% from 3Q 2024). Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.4% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
New Risk • Nov 05New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr23m Forecast net loss in 2 years: kr4.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr4.0m net loss in 2 years). Share price has been volatile over the past 3 months (9.2% average weekly change). Market cap is less than US$100m (kr195.8m market cap, or US$20.4m).
Recent Insider Transactions • Aug 17Independent Director recently bought kr105k worth of stockOn the 14th of August, Chatarina Schneider bought around 60k shares on-market at roughly kr1.76 per share. This transaction amounted to 81% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.3m more in shares than they have sold in the last 12 months.
Board Change • Aug 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Johan Magnusson was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Jul 23OrganoClick AB (publ) (STO:ORGC) Analysts Are Cutting Their Estimates: Here's What You Need To KnowAs you might know, OrganoClick AB (publ) ( STO:ORGC ) last week released its latest quarterly, and things did not turn...
Reported Earnings • Jul 20Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: kr0.065 loss per share (further deteriorated from kr0.029 loss in 2Q 2024). Revenue: kr30.0m (down 23% from 2Q 2024). Net loss: kr6.37m (loss widened 124% from 2Q 2024). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 200%. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Jul 18The analyst covering OrganoClick previously expected the company to break even in 2027. New forecast suggests losses will reduce by 53% per year to 2026. The company is expected to make a profit of kr3.20m in 2027. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
공고 • Jul 18OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.31619 million.OrganoClick AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.31619 million. Security Name: Shares Security Type: Common Stock Securities Offered: 11,543,290 Price\Range: SEK 1.76 Transaction Features: Rights Offering
분석 기사 • Jul 16OrganoClick (STO:ORGC) Is Making Moderate Use Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Major Estimate Revision • Jul 10Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr135.0m to kr130.0m. Losses expected to increase from kr0.14 per share to kr0.16. Chemicals industry in Sweden expected to see average net income growth of 37% next year. Consensus price target of kr2.50 unchanged from last update. Share price rose 7.5% to kr2.15 over the past week.
공고 • May 20OrganoClick AB (publ) Approves Board ChangesOrganoClick AB (publ) announced at the AGM held on May 20, 2025, approved Johan Magnusson was elected as Chairman of the Board. The Board also gave a big thank to the outgoing Chairman of the board Jan Johansson for his contribution to the board and the company during his 9 years as Chairman of the board.
Recent Insider Transactions • May 15Independent Director recently bought kr129k worth of stockOn the 8th of May, Johan Magnusson bought around 60k shares on-market at roughly kr2.15 per share. This trade did not impact their existing holding. In the last 3 months, there was an even bigger purchase from another insider worth kr1.0m. Insiders have collectively bought kr1.2m more in shares than they have sold in the last 12 months.
분석 기사 • May 14It's Probably Less Likely That OrganoClick AB (publ)'s (STO:ORGC) CEO Will See A Huge Pay Rise This YearKey Insights OrganoClick to hold its Annual General Meeting on 20th of May Total pay for CEO Marten Hellberg includes...
Major Estimate Revision • May 13Consensus EPS estimates fall by 40%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr140.0m to kr135.0m. Losses expected to increase from kr0.10 per share to kr0.14. Chemicals industry in Sweden expected to see average net income growth of 41% next year. Consensus price target of kr2.50 unchanged from last update. Share price fell 11% to kr2.05 over the past week.
분석 기사 • May 09kr2.50: That's What Analysts Think OrganoClick AB (publ) (STO:ORGC) Is Worth After Its Latest ResultsThe analyst might have been a bit too bullish on OrganoClick AB (publ) ( STO:ORGC ), given that the company fell short...
New Risk • May 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr5.5m free cash flow). Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$100m (kr260.0m market cap, or US$26.9m).
분석 기사 • May 05Cautious Investors Not Rewarding OrganoClick AB (publ)'s (STO:ORGC) Performance CompletelyOrganoClick AB (publ)'s ( STO:ORGC ) price-to-sales (or "P/S") ratio of 1.9x might make it look like a buy right now...
New Risk • May 04New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr5.5m free cash flow). Minor Risk Market cap is less than US$100m (kr245.3m market cap, or US$25.4m).
Major Estimate Revision • Apr 30Consensus EPS estimates fall by 67%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from kr143.0m to kr140.0m. Losses expected to increase from kr0.06 per share to kr0.10. Chemicals industry in Sweden expected to see average net income growth of 38% next year. Consensus price target of kr2.50 unchanged from last update. Share price fell 3.3% to kr2.34 over the past week.
공고 • Apr 16OrganoClick AB (publ), Annual General Meeting, May 20, 2025OrganoClick AB (publ), Annual General Meeting, May 20, 2025, at 13:00 W. Europe Standard Time. Location: at convendum, brahegatan 10, stockholm Sweden
Reported Earnings • Apr 09Full year 2024 earnings: EPS in line with expectations, revenues disappointFull year 2024 results: kr0.18 loss per share (further deteriorated from kr0.16 loss in FY 2023). Revenue: kr127.2m (down 13% from FY 2023). Net loss: kr18.0m (loss widened 14% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Feb 27Director recently bought kr1.0m worth of stockOn the 25th of February, Charlotte Jansdotter Karlberg bought around 400k shares on-market at roughly kr2.50 per share. This transaction increased Charlotte Jansdotter's direct individual holding by 5x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.0m more in shares than they have sold in the last 12 months.
Reported Earnings • Feb 15Full year 2024 earnings: EPS in line with expectations, revenues disappointFull year 2024 results: kr0.18 loss per share (further deteriorated from kr0.16 loss in FY 2023). Revenue: kr127.2m (down 13% from FY 2023). Net loss: kr18.0m (loss widened 14% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
분석 기사 • Feb 14Would OrganoClick (STO:ORGC) Be Better Off With Less Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
New Risk • Feb 13New major risk - Revenue and earnings growthEarnings have declined by 1.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.4% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr4.5m). Market cap is less than US$100m (kr263.0m market cap, or US$24.2m).
공고 • Feb 13OrganoClick AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025OrganoClick AB (publ) announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 03, 2025
공고 • Dec 03+ 3 more updatesOrganoClick AB (publ) to Report Q1, 2025 Results on May 06, 2025OrganoClick AB (publ) announced that they will report Q1, 2025 results on May 06, 2025
Reported Earnings • Nov 07Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: kr0.047 loss per share (further deteriorated from kr0.042 loss in 3Q 2023). Revenue: kr28.9m (down 14% from 3Q 2023). Net loss: kr4.62m (loss widened 12% from 3Q 2023). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 150%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
New Risk • Nov 06New major risk - Revenue and earnings growthEarnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr284.5m market cap, or US$26.2m).
New Risk • Oct 29New major risk - Revenue and earnings growthEarnings have declined by 5.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr288.5m market cap, or US$27.0m).
Breakeven Date Change • Jul 22Forecast to breakeven in 2025The analyst covering OrganoClick expects the company to break even for the first time. New forecast suggests the company will make a profit of kr6.00m in 2025. Average annual earnings growth of 109% is required to achieve expected profit on schedule.
Reported Earnings • Jul 22Second quarter 2024 earnings released: kr0.029 loss per share (vs kr0.027 loss in 2Q 2023)Second quarter 2024 results: kr0.029 loss per share (further deteriorated from kr0.027 loss in 2Q 2023). Revenue: kr38.7m (down 5.6% from 2Q 2023). Net loss: kr2.85m (loss widened 6.6% from 2Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Jul 07Consensus EPS estimates fall by 17%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr158.0m to kr155.0m. Losses expected to increase from kr0.06 per share to kr0.07. Chemicals industry in Sweden expected to see average net income growth of 33% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.78 over the past week.
분석 기사 • Jun 19A Piece Of The Puzzle Missing From OrganoClick AB (publ)'s (STO:ORGC) 26% Share Price ClimbOrganoClick AB (publ) ( STO:ORGC ) shareholders have had their patience rewarded with a 26% share price jump in the...
공고 • Jun 15OrganoClick AB (publ) Announces CFO ChangesOrganoClick AB (publ) has appointed Carin Eklund as the new CFO for the group. She will lead OrganoClick's finance and economics department and be part of the group's management team. Carin has more than 20 years of experience from various finance functions from, among others, Bristol Myers Squibb group, ByggFakta group and Team Olivia group. Carin has a M. Sc. in Economics with a specialization in financial mathematics at Karlstad University. For more than 25 years, Carin has worked in finance departments at both manufacturing companies and service companies, in both smaller companies and large groups. Previous experiences include roles as CFO for Olivia Hemomsorg, Finance manager for the medical technology company Convatec (part of the Bristol Myers Squibb Group), Head of Business Control Nordic region at ByggFakta Group and as Strategic Controller at the kitchen manufacturer Nobia. Carin takes over as CFO on July 15, and as previously announced, OrganoClick's current CFO Jessica Sundborg will leave the company 21 of August.
공고 • May 16OrganoClick AB (publ) Approves Board ChangesOrganoClick AB (publ) at its Annual General Meeting held on 15 May 2024 approved the election of Johan Magnusson as board member. The Board also gave a big thank to the outgoing board member Malin Bugge for her contribution to the board and the company during her 4 years as a board member.
분석 기사 • May 09Shareholders May Find It Hard To Justify Increasing OrganoClick AB (publ)'s (STO:ORGC) CEO Compensation For NowKey Insights OrganoClick's Annual General Meeting to take place on 15th of May CEO Marten Hellberg's total compensation...
분석 기사 • May 03Earnings Release: Here's Why Analysts Cut Their OrganoClick AB (publ) (STO:ORGC) Price Target To kr3.00Investors in OrganoClick AB (publ) ( STO:ORGC ) had a good week, as its shares rose 2.2% to close at kr3.30 following...
Reported Earnings • May 02First quarter 2024 earnings: EPS in line with expectations, revenues disappointFirst quarter 2024 results: kr0.022 loss per share (further deteriorated from kr0.01 loss in 1Q 2023). Revenue: kr38.2m (down 12% from 1Q 2023). Net loss: kr2.11m (loss widened 112% from 1Q 2023). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
Major Estimate Revision • May 01Consensus EPS estimates upgraded to kr0.06 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from kr166.0m to kr158.0m. 2024 losses expected to reduce from -kr0.09 to -kr0.06 per share. Chemicals industry in Sweden expected to see average net income growth of 48% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.24 over the past week.
New Risk • Apr 30New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr298.7m market cap, or US$27.3m).
공고 • Apr 23OrganoWood AB (publ) Announces Three-Year Results from the Field Study EN 12037 for Organowood NowaOrganowood Nowa is currently subjected to one of the toughest standard field tests available for wood above ground, EN 12037! The test runs for 5 years in Malaysia and Denmark and now publish the three-year results. The independent external institute Dansk Teknologisk Institut therefore carries out the EN 12037 field test with Organowood Nowa in both Denmark and Malaysia. The references, which consist of untreated pine wood and the wood impregnated with CCA (chromium, copper and arenic), which has been banned for 20 years, were also included in the test. The scale for assessing degradation ranges from grade 0-4, where 0 meas that the wood is unaffected and 4 means that the wood is completely degraded. The untreated reference in Malaysia was completely degraded after 3 years, by rot fungus but also in some cases by termites. Pine pressure-impregnated with CCA was, as expected, unaffected. But also OrganoWood Nowa was completely unaffected with grade 0 on the scale! The result shows a very good wood protection even in the warm and humid environment that a rainforest offers. The field study will continue and will continuously report results from both Denmark and Malaysia.
공고 • Apr 19Jessica Sundborg to Leave as CFO of OrganoClick AB (publ)OrganoClick AB (publ) announced that its CFO since 2013, Jessica Sundborg is leaving her position to move on to a new position outside the company. Jessica will remain as CFO until she leaves her position after the summer. The work to recruit a successor has begun.
New Risk • Apr 17New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr308.5m market cap, or US$28.2m).
공고 • Apr 11Organoclick AB (Publ) Announces That Malin Bugge, Board Member, Has Declined Re-ElectionOrganoClick AB (publ) announced that Malin Bugge, who has been a board member since 2020, has declined re-election.
Reported Earnings • Apr 09Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: kr0.16 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr145.9m (up 27% from FY 2022). Net loss: kr15.8m (loss narrowed 65% from FY 2022). Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
분석 기사 • Mar 25Sentiment Still Eluding OrganoClick AB (publ) (STO:ORGC)With a price-to-sales (or "P/S") ratio of 2.4x OrganoClick AB (publ) ( STO:ORGC ) may be sending bullish signals at the...
공고 • Mar 23OrganoClick and PulPac Launches Plastic-Free Coffee Lid Reducing Co2 Footprint with 80%OrganoClick and PulPac has collaborated for several years in developing 100% biobased and biodegradable dry-molded products. By combining PulPac's dry molded fiber technology with OrganoClick's biobased and biodegradable binders, a biobased high-performing coffee lid, compliant with paper recycling have been developed. The innovative coffee lid is now launched for the take away market. PulPac's technology in combination with OrganoClick's biobased binders sets a new standard for high performing and sustainable packaging. It requires less energy and water than the traditional method, resulting in a reduced carbon footprint with up to 80% compared to traditional alternatives. One of the first products out is a plastic-free coffee lid which align with the recent EU legislation for take away product. Annual global consumption of coffee lids is estimated at 100,000,000,000 and with the new coffee lid, the CO2 footprint is reduced with up to 80%. The coffee lid is made green inside with the support of OrganoClick's biobased, biodegradable and home compostable binder, in part manufactured from waste streams from the food industry. The use of OrganoClick's binder resulting in a paper lid with much higher performance. The objectives are also to replace as much as possible of traditional plastic lids available on the market, thereby reducing the risk for microplastics ending up in the environment.
Major Estimate Revision • Feb 22Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr183.0m to kr170.0m. Losses expected to increase from kr0.08 per share to kr0.09. Chemicals industry in Sweden expected to see average net income growth of 42% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.16 over the past week.
분석 기사 • Feb 18Earnings Update: OrganoClick AB (publ) (STO:ORGC) Just Reported And Analysts Are Trimming Their ForecastsLast week, you might have seen that OrganoClick AB (publ) ( STO:ORGC ) released its full-year result to the market. The...
Reported Earnings • Feb 16Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: kr0.16 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr145.9m (up 27% from FY 2022). Net loss: kr15.8m (loss narrowed 65% from FY 2022). Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
New Risk • Jan 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr13m). Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (kr297.8m market cap, or US$28.5m).
Major Estimate Revision • Jan 19Consensus EPS estimates upgraded to kr0.14 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -kr0.17 to -kr0.14 per share. Revenue forecast steady at kr148.0m. Chemicals industry in Sweden expected to see average net income growth of 1.1% next year. Consensus price target of kr3.00 unchanged from last update. Share price was steady at kr3.18 over the past week.
분석 기사 • Jan 09OrganoClick (STO:ORGC) Seems To Use Debt Quite SensiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
공고 • Dec 20OrganoClick AB (publ), Annual General Meeting, May 15, 2024OrganoClick AB (publ), Annual General Meeting, May 15, 2024.
공고 • Dec 19+ 4 more updatesOrganoClick AB (publ) to Report Fiscal Year 2024 Results on Feb 13, 2025OrganoClick AB (publ) announced that they will report fiscal year 2024 results on Feb 13, 2025
Recent Insider Transactions • Nov 16Co-founder & CEO recently bought kr202k worth of stockOn the 13th of November, Marten Hellberg bought around 56k shares on-market at roughly kr3.63 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Marten has been a buyer over the last 12 months, purchasing a net total of kr211k worth in shares.
New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr13m). Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (kr372.2m market cap, or US$34.3m).
Reported Earnings • Nov 10Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: kr0.042 loss per share (improved from kr0.093 loss in 3Q 2022). Revenue: kr33.4m (up 50% from 3Q 2022). Net loss: kr4.13m (loss narrowed 55% from 3Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 33%. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
New Risk • Nov 09New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr14m). Market cap is less than US$100m (kr307.6m market cap, or US$28.3m).
New Risk • Nov 03New major risk - Revenue and earnings growthEarnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr14m). Market cap is less than US$100m (kr330.1m market cap, or US$30.3m).
Breakeven Date Change • Nov 03Forecast to breakeven in 2025The analyst covering OrganoClick expects the company to break even for the first time. New forecast suggests the company will make a profit of kr7.90m in 2025. Average annual earnings growth of 107% is required to achieve expected profit on schedule.
공고 • Oct 17OrganoClick AB (publ) Announces Nomination CommitteeOrganoClick AB (publ) announced composition of nomination committee. It is composed of Peter Lindell, representing Cidro Förvaltning and himself, Håkan Gustavson representing Beijer Ventures, the Beijer foundations, and himself, and Mårten Hellberg, representing M. Hellberg AB and himself. Peter Lindell was appointed as Chairman of the Nomination committee as the individually largest shareholder in OrganoClick AB.
Recent Insider Transactions • Aug 24Chairman recently bought kr147k worth of stockOn the 18th of August, Jan Johansson bought around 35k shares on-market at roughly kr4.20 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jan has been a buyer over the last 12 months, purchasing a net total of kr352k worth in shares.
Reported Earnings • Aug 18Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: kr0.03 loss per share (improved from kr0.09 loss in 2Q 2022). Revenue: kr41.0m (up 6.5% from 2Q 2022). Net loss: kr2.67m (loss narrowed 70% from 2Q 2022). Revenue missed analyst estimates by 5.2%. Earnings per share (EPS) exceeded analyst estimates by 25%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 13% per year.
New Risk • Jul 19New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr40m Forecast net loss in 2 years: kr1.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr31m). Currently unprofitable and not forecast to become profitable over next 2 years (kr1.4m net loss in 2 years). Market cap is less than US$100m (kr471.1m market cap, or US$45.8m).
Major Estimate Revision • Jul 19Consensus EPS estimates fall by 25%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr166.5m to kr152.6m. Losses expected to increase from kr0.12 per share to kr0.15. Chemicals industry in Sweden expected to see average net income decline 1.4% next year. Consensus price target of kr9.00 unchanged from last update. Share price fell 4.7% to kr4.66 over the past week.
공고 • Jun 01Organoclick Launches Biobased and Eco-Labelled Textile WaterproofingAfter several years of research and development, OrganoClick is launching, within its brand OrganoTex, a newly developed and eco-labelled textile waterproofing with world-unique performance on the trade fair ISPO Outdoor 4-6 June in Munich. Through green chemistry that mimics nature's own water repellency, an excellent environmental profile and high technical performance are achieved. The products are biobased, biodegradable and eco-labelled and completely free of PFAS, fossil plastics, and synthetic waxes. The technology is based on combining the natural fatty acids of plants and the surface structure of leaves with the Nobel Prize-winning chemistry organocatalysis. The inspiration is the lotus leaf with its 3D structure and extreme water repellency. To succeed in this, the patented OrganoClick technology is used to "click" the natural fatty acids on the textile fibers. The result is a new generation of OrganoTex products that have improved water repellency and withstand morewashing cycles. The products are biobase and biodegradable, and contain neither PFAS, fossil-based plastics nor synthetic waxes. First out are the products OrganoTex Wash-In Textile Waterproofing and OrganoTex Spray-On Textile Waterproofing. Thanks to their excellent environmental profile, they have received the environmental label Oeko-Tex Eco Passport and USDA BioPreferred Certified Biobased Product. The products are also verified to be readily biodegradable according to the high requirements of the OECD 301F test. A world-unique product that both combines high performance and at the same time is biobased, plastic-free and biodegradable and, of course, PFAS-free. This innovation is fully in line with OrganoClick's overall mission to accelerate the phasing out of plastics and fossil chemicals towards overall vision of a nature free of plastics and toxic chemicals.
공고 • May 19Organoclick AB (Publ) Announces Board ChangesOrganoClick AB (publ) at its Annual General Meeting on 17 May 2023 the company approved and elect Chatarina Schneider as board members. And Board also gave a big thank to the outgoing board member Claes-Göran Beckeman for his important contribution to the board and the company during his 15 years as a board member.
Major Estimate Revision • May 12Consensus estimates of losses per share improve by 25%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from kr162.1m to kr166.5m. EPS estimate increased from -kr0.16 per share to -kr0.12 per share. Chemicals industry in Sweden expected to see average net income growth of 0.2% next year. Consensus price target of kr9.00 unchanged from last update. Share price fell 17% to kr3.97 over the past week.
분석 기사 • May 11Is OrganoClick AB (publ) (STO:ORGC) Potentially Undervalued?While OrganoClick AB (publ) ( STO:ORGC ) might not be the most widely known stock at the moment, it saw a decent share...
분석 기사 • Apr 18There's No Escaping OrganoClick AB (publ)'s (STO:ORGC) Muted Revenues Despite A 33% Share Price RiseDespite an already strong run, OrganoClick AB (publ) ( STO:ORGC ) shares have been powering on, with a gain of 33% in...
Reported Earnings • Apr 09Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: kr0.45 loss per share (further deteriorated from kr0.34 loss in FY 2021). Revenue: kr115.0m (up 4.5% from FY 2021). Net loss: kr44.4m (loss widened 36% from FY 2021). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Apr 06Chairman recently bought kr206k worth of stockOn the 3rd of April, Jan Johansson bought around 50k shares on-market at roughly kr4.11 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jan's only on-market trade for the last 12 months.
Recent Insider Transactions • Feb 27Environmental & Sustainability Director recently bought kr120k worth of stockOn the 20th of February, Mattias Bodin bought around 30k shares on-market at roughly kr4.00 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.7m more in shares than they have sold in the last 12 months.